Page 12 - ஹைதராபாத் அடிப்படையிலானது பாரத் பயோடெக் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Union Minister Mansukh Mandaviya visits COVID-19 vaccine manufacturing facilities in Gujarat
aninews.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aninews.in Daily Mail and Mail on Sunday newspapers.
Johns Hopkins-supported App Will Guide Covid Patients in India
indiawest.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiawest.com Daily Mail and Mail on Sunday newspapers.
Representative Image
Bharat Biotech releases Phase 3 trial results of Covaxin, claims vaccine efficacy of 78.8 pc against COVID-19 By Sahil Pandey | Updated: Jul 03, 2021 09:15 IST
Hyderabad (Telangana) [India], July 3 (ANI): Hyderabad-based Bharat Biotech on Saturday concluded a final analysis for its vaccine Covaxin efficacy from phase-3 clinical trial claiming it to be 77.8 per cent effective against COVID-19.
It also added that Covaxin gives 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant. Efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group. Efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19, the company said.
COVAXIN Has An Efficacy Of 78 8% Against COVID-19, Offers 62 5% Protection Against Delta Strain
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
Govt panel says no to Serum Institute s Covovax trial on children aged 2-17 years
Govt panel says no to Serum Institute s Covovax trial on children aged 2-17 years
An expert government panel has recommended against granting permission to the Serum Institute of India (SII) to conduct clinical trial of Covid-19 vaccine Covovax on children in the age group 2-7 years.
advertisement
UPDATED: July 1, 2021 10:24 IST
A government panel has said no to Serum Institute s Covovax trial on children aged 2-17 years. (Image for representation: PTI)
An expert panel on Wednesday recommended against granting permission to Pune s Serum Institute of India (SII) for conducting the phase 2/3 trial of Covid-19 vaccine Covovax on children aged between two to 17 years, sources said. The panel asked the pharmaceutical company to complete trials on adults first.